Biosimilars Canada Code of Conduct

You can have confidence in your biosimilar medicines

Switching to biosimilars is safe and effective for patients

Who we are

Biosimilars Canada is a national association representing the biosimilar medicines industry in Canada. We provide leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines, and advocate for policies that support their timely approval, reimbursement, market acceptance and expanded use.

About Biosimilars

As patents for original brand biologic medicines expire other manufacturers can produce new versions called biosimilars. Health Canada authorizes biosimilars for sale using the same rigorous regulatory standards as for all other biologic drugs, and there are no clinically meaningful differences in efficacy and safety between a biosimilar and the original brand biologic medicine.

Resources

Learn more about biosimilars and their benefits for patients and healthcare systems.

Latest news

October 10, 2025

News releases

CGPA and Biosimilars Canada welcome the Government of Quebec’s initiative to improve access to cost-saving medicines

Montreal, QC, October 10, 2025 – The Canadian Generic Pharmaceutical Association (CGPA) and its Biosimilars Canada division welcome the decision by the Government of Quebec to increase the number of formulary updates to the Régie de l’assurance maladie du Québec (RAMQ) lists of medications from...

March 3, 2025

News releases

Biosimilars Canada Announces Board Chair and Vice-Chair for 2025

Toronto – March 3, 2025 – Biosimilars Canada is pleased to announce the unanimous election of Mike Casia, President and Managing Director of Organon Canada, as Chair of Biosimilars Canada for 2025. Mike Woolcock, Senior Vice President of Biosimilars and Specialty...

November 14, 2024

News releases

#SaveBigWithBiosimilars Campaign Provides Sustainable Solutions for Employer-Sponsored Health Benefit Plans

Toronto – November 14, 2024 – Biosimilars Canada has launched a new #SaveBigWithBiosimilars campaign to educate Canadian businesses about the benefits of adopting biosimilar transition policies for their employee health benefit plans. While public drug programs across Canada have adopted...